Reaction

Menopause reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,517 reports · 63 co-occurring drugs

As of the last recalculation, Menopause appears in 2,517 FAERS reports alongside 63 co-occurring drug terms. The strongest observed disproportionality signal is COPPER (PRR 35.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Copper	171	35.1	35.3
Progesterone	47	17.3	17.3
Desoximetasone	25	10.9	11.0
Anastrozole	47	10.8	10.8
Thyroid, Porcine	11	8.6	8.6
Anastrozole Tablets	22	8.5	8.6
Conjugated Estrogens And Medroxyprogesterone Acetate	24	8.5	8.5
Estradiol Gel 0.1%	44	8.2	8.2
Estradiol Transdermal	44	8.2	8.2
Estradiol	82	8.1	8.1
Ocrelizumab	57	7.8	7.8
Liothyronine Sodium	8	7.6	7.6
Avapritinib	11	7.5	7.5
Asfotase Alfa	9	7.5	7.5
Goserelin	12	7.4	7.4
Botulinum Toxin Type A	11	7.4	7.4
Diclofenac Potassium	9	6.9	6.9
Dextroamphetamine Sulfate, Dextroamphetamine Saccharate, Amphetamine Sulfate And Amphetamine Aspartate	34	6.9	6.9
Mometasone	15	6.8	6.8
Tolterodine Tartrate	7	6.5	6.5
Zonisamide	11	6.2	6.2
Fluticasone Furoate	9	6.2	6.2
Lithium	18	5.9	5.9
Lithium Bromatum	18	5.9	5.9
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, And Amphetamine Sulfate	24	5.7	5.7
Armodafinil	14	5.5	5.5
Dalfampridine	47	5.5	5.5
Brexpiprazole	11	5.5	5.5
Sumatriptan	25	5.5	5.5
Sodium Oxybate	42	5.3	5.3
Conjugated Estrogens	37	5.3	5.3
Estrogens, Conjugated	37	5.2	5.2
Medroxyprogesterone Acetate	29	4.9	4.9
Teriflunomide	25	4.6	4.6
Interferon Beta-1A	100	4.4	4.4
Golimumab	44	4.3	4.3
Lisdexamfetamine Dimesylate	17	4.3	4.3
Pegvaliase-Pqpz	4	4.0	4.0
Desvenlafaxine Succinate	13	4.0	4.0
Leuprolide Acetate	33	3.6	3.6
Varenicline Tartrate	32	3.3	3.3
Belimumab	12	3.1	3.1
Interferon Beta-1B	7	3.0	3.0
Obinutuzumab	6	3.0	3.0
Voclosporin	3	2.9	2.9
Docetaxel Anhydrous	23	2.8	2.8
Docetaxel	23	2.8	2.8
Cariprazine	3	2.7	2.7
Elexacaftor, Tezacaftor, And Ivacaftor	4	2.7	2.7
Risankizumab-Rzaa	26	2.6	2.6
Orlistat	8	2.6	2.6
Certolizumab Pegol	35	2.5	2.5
Dimethyl Fumarate	36	2.4	2.4
Galcanezumab-Gnlm	9	2.4	2.4
Palbociclib	27	2.4	2.4
Levonorgestrel	54	2.2	2.2
Natalizumab	48	2.2	2.2
Lifitegrast	4	2.0	2.0
Ambrisentan	28	1.9	1.9
Somatropin	15	1.7	1.7
Hydrocodone Bitartrate	8	1.5	1.5
Erenumab-Aooe	9	1.4	1.4
Tirzepatide	20	1.0	1.0

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.